Sarepta Gene Therapy Deaths

Order byBest matchMost fresh

FDA, Sarepta Therapeutics

Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy

Shares of drugmaker Sarepta Therapeutics continued to sink Tuesday after the company said it would comply with a Food and Drug Administration request to pause shipments of its gene therapy following s...

· 1h

Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy

MedPage Today · 1d

Drugmaker Refuses FDA's Request to Pull Gene Therapy Tied to Patient Deaths

· 4h

Sarepta Faces Fresh Setback. Why Now’s Not the Time to Buy the Stock.

Sarepta Therapeutics was falling again in premarket trading Tuesday as its future looks increasingly shaky after it agreed to halt shipments of its Elevidys drug under pressure from the Food and Drug ...

STAT · 7h

In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy

STAT · 1d

Pharmalittle: We’re reading about Sarepta resisting FDA over Elevidys, agency naming top drug regulator, and more

Fierce Biotech1d

Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy

The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb girdle muscular dystrophy (LGMD) trials, while also revoking the biopharma’s gene therapy platform technology designation.

4don MSN

Sarepta shares slump after third patient death this year

Shares of Sarepta Therapeutics declined 17% in early trading on Friday after another patient who had received an experimental gene therapy died, deepening investor concerns over the use of the company's treatments.